The effect of sesame lignans on atherosclerosis

The effect of sesame lignans consumption on carotid intima-media thickness, serum endothelial markers, some angiogenic mediators gene expression in patients candidated for angiography

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201709246722N2

Enrollment

Registered

2017-11-04

Start date

2016-08-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Atherosclerosis. Condition 2: Atherosclerosis. Condition 3: Atherosclerosis. Condition 4: Atherosclerosis. Condition 5: Atherosclerosis. Condition 6: Atherosclerosis. Condition 7: Atherosclerosis. Condition 8: Atherosclerosis. Atherosclerosis of aorta Atherosclerosis of other arteries Generalized and unspecified atherosclerosis Dissection of aorta [any part] Aneurysm and dissection of carotid artery Disorder of arteries and arterioles, unspecified Peripheral angiopathy in dis

Interventions

Intervention 1: placebo capsule containing starch one capsule per day 10 weeks. Intervention 2: sesame lignans each capsule containing 500 mg one capsule per day 10 weeks.

Placebo

Prevention

placebo capsule containing starch one capsule per day 10 weeks

sesame lignans each capsule containing 500 mg one capsule per day 10 weeks

Eligibility

Sex/Gender

All

Age

40 Years to 70 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria:40 to 70 years old ; candidate for angiography; Carotid Intima-media thickness more than standard (0.8 mm); patients voluntarily confirm their willingness to participate in the study Exclusion criteria: MI or illness associated with artery clogging which is untreated; any change in the amount or type of medications consumed during intervention; inflammatory disease require NSAIDs medications; lack of desire to continue the collaboration;not taking 10 percent of supplements (not to use for one week); the incidence of allergic reaction to supplement; obesity (body mass index of 35 and more); comorbidity of a chronic disease (renal or hepatic insufficiency, pulmonary failure, a history of cancer or asthma); the use of NSAIDs; usage of dietary/ herbal /multi-vitamin supplements at least two weeks before the start of the intervention

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Carotid Intima-media thikness. Timepoint: before and after intervention. Method of measurement: color dopler ultrasonography.;VEGF serum concentration. Timepoint: before and after intervention. Method of measurement: ELISA assay.;ICAM1 serum concentration. Timepoint: before and after intervention. Method of measurement: ELISA assay.;VCAM1 serum concentration. Timepoint: before and after intervention. Method of measurement: ELISA assay.;VWF serum concentration. Timepoint: before and after intervention. Method of measurement: ELISA assay.;HsCRP serum concentration. Timepoint: before and after intervention. Method of measurement: ELISA assay.;VEGF gene expression. Timepoint: before and after intervention. Method of measurement: qRTPCR.;ICAM1 gene expression. Timepoint: before and after intervention. Method of measurement: qRTPCR.;Gamma INF gene expression. Timepoint: before and after intervention. Method of measurement: qRTPCR.	—

Measure

Time frame

Carotid Intima-media thikness. Timepoint: before and after intervention. Method of measurement: color dopler ultrasonography.;VEGF serum concentration. Timepoint: before and after intervention. Method of measurement: ELISA assay.;ICAM1 serum concentration. Timepoint: before and after intervention. Method of measurement: ELISA assay.;VCAM1 serum concentration. Timepoint: before and after intervention. Method of measurement: ELISA assay.;VWF serum concentration. Timepoint: before and after intervention. Method of measurement: ELISA assay.;HsCRP serum concentration. Timepoint: before and after intervention. Method of measurement: ELISA assay.;VEGF gene expression. Timepoint: before and after intervention. Method of measurement: qRTPCR.;ICAM1 gene expression. Timepoint: before and after intervention. Method of measurement: qRTPCR.;Gamma INF gene expression. Timepoint: before and after intervention. Method of measurement: qRTPCR.

—

Secondary

Measure	Time frame
Systolic blood pressure. Timepoint: before and after intervention. Method of measurement: medical barometer.;Serum FBS concentration. Timepoint: before and after intervention. Method of measurement: enzymatic kit.;Serum HDLc concentration. Timepoint: before and after intervention. Method of measurement: enzymatic kit.;Serum TG concentration. Timepoint: before and after intervention. Method of measurement: enzymatic kit.;Serum total colesterol concentration. Timepoint: before and after intervention. Method of measurement: enzymatic kit.;Serum LDLc concentration. Timepoint: before and after intervention. Method of measurement: enzymatic kit.;Diastolic blood pressure. Timepoint: before and after intervention. Method of measurement: medical barometer.;Weight. Timepoint: before and after intervention. Method of measurement: medical scale.;Waist circumference. Timepoint: before and after intervention. Method of measurement: measuring tape.;Hip circumference. Timepoint: before and after intervention. Method of measurement: measuring tape.	—

Measure

Time frame

Systolic blood pressure. Timepoint: before and after intervention. Method of measurement: medical barometer.;Serum FBS concentration. Timepoint: before and after intervention. Method of measurement: enzymatic kit.;Serum HDLc concentration. Timepoint: before and after intervention. Method of measurement: enzymatic kit.;Serum TG concentration. Timepoint: before and after intervention. Method of measurement: enzymatic kit.;Serum total colesterol concentration. Timepoint: before and after intervention. Method of measurement: enzymatic kit.;Serum LDLc concentration. Timepoint: before and after intervention. Method of measurement: enzymatic kit.;Diastolic blood pressure. Timepoint: before and after intervention. Method of measurement: medical barometer.;Weight. Timepoint: before and after intervention. Method of measurement: medical scale.;Waist circumference. Timepoint: before and after intervention. Method of measurement: measuring tape.;Hip circumference. Timepoint: before and after intervention. Method of measurement: measuring tape.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMarzieh Mokhber

Tehran University of Medical Sciences

"marmokhber@razi.tums.ac.ir ; m.mokhber@chmail.ir+98 21 8889 2209

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026